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Background: Lower concentrations of the insulin–like growth factor binding protein-1 (IGFBP-1) and elevated
concentrations of insulin or C-peptide have been associated with an increase in colorectal cancer risk (CRC).
However few studies have evaluated IGFBP-1 and C-peptide in relation to adenomatous polyps, the only known
precursor for CRC.
Methods: Between November 2001 and December 2002, we examined associations between circulating
concentrations of insulin, C-peptide, IGFBP-1 and apoptosis among 190 individuals with one or more adenomatous
polyps and 488 with no adenomatous polyps using logistic regression models.
Results: Individuals with the highest concentrations of C-peptide were more likely to have adenomas (OR = 2.2,
95% CI 1.4-4.0) than those with the lowest concentrations; associations that appeared to be stronger in men
(OR = 4.4, 95% CI 1.7-10.9) than women. Individuals with high insulin concentrations also had a higher risk of
adenomas (OR = 3.5, 95% CI 1.7-7.4), whereas higher levels of IGFBP-1 were associated with a reduced risk of
adenomas in men only (OR = 0.3, 95% CI 0.1-0.7). Overweight and obese individuals with higher C-peptide levels
(>1st Q) were at increased risk for lower apoptosis index (OR = 2.5, 95% CI 0.9-7.1), an association that remained
strong in overweight and obese men (OR = 6.3, 95% CI 1.0-36.7). Higher levels of IGFBP-1 in overweight and obese
individuals were associated with a reduced risk of low apoptosis (OR = 0.3, 95% CI 0.1-1.0).
Conclusions: Associations between these peptides and the apoptosis index in overweight and obese individuals,
suggest that the mechanism by which C-peptide could induce adenomas may include its anti-apoptotic properties.
This study suggests that hyperinsulinemia and IGF hormones predict adenoma risk, and that outcomes associated
with colorectal carcinogenesis maybe modified by gender.
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Colorectal adenomas are precursors to colorectal cancer
(CRC) [1], and CRC is the second most common cancer in
men and women worldwide [2]. Reducing CRC risk will
depend on identification of potential markers of precancer-
ous adenomas. Components of the insulin-IGF axis have
been key targets to identify potential biomarkers of aden-
oma risk, in part because western diets, physical inactivity
and other factors associated with obesity, insulin resistance
and diabetes history, are known risk factors for colon* Correspondence: tokeku@med.unc.edu
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reproduction in any medium, provided the orcancer [3]. The mechanisms by which obesity and insulin
resistance promote CRC are not well understood, although
insulin is a crucial component in the regulation of energy
metabolism. Elevated circulating insulin levels have also
been associated with mitogenic [4,5] and anti-apoptotic
effects in overweight and obese individuals [6]. Thus,
higher circulating insulin levels may promote colorectal
adenomas and cancer through increased proliferation or
reduced apoptosis [5,7].
Insulin, insulin growth factor I (IGF-I) and IGF-II are
structurally related proteins that share common recep-
tors [8]. At high concentrations, insulin may utilize insu-
lin receptors (IR), IGF1 receptors (IGF1R) or hybrid IR/
IGF1R to regulate cell proliferation and apoptosis [9-11].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thesis or can enhance IGF-I bioavailability by inhibiting
the production of IGF-binding proteins (IGFBP) such as
IGFBP-1 [12,13]. IGFBP-1 plays an important role in
glucose homeostasis, and circulating IGFBP-1 is in-
versely related to C-peptide and insulin levels [14,15].
Furthermore, IGFBP-1 can also induce apoptosis in
breast and prostate cancer cells in vitro as well as sup-
press tumor growth in an insulin dependent and inde-
pendent manner [16]. Thus, IGFBP-1 levels may
influence colorectal adenomas and cancer development
via two mechanisms: inhibition of the proliferative
actions of insulin and IGF, and promotion of apoptosis.
Disentangling these relationships will be important in
determining the utility of these peptide hormones as dis-
ease markers.
We have previously reported a positive association be-
tween elevated fasting plasma insulin levels and aden-
omas in the Diet and Health Study III [17]. More
recently, we observed that local expression of IGFBP-3
was inversely related to adenomas [18]. Based on these
previous observations, we hypothesized that elevated
IGFBP-1 is associated with reduced risk of adenomas
and low apoptosis in normal mucosa. Few studies have
evaluated IGFBP-1 and C-peptide or insulin in relation
to colorectal adenomas and cancer and the results are
inconsistent [19-24]. Inconsistencies may be due in part
to differences in race/ethnicity [22] and gender [24].
Moreover, the relationships between these markers and
apoptosis have not, to our knowledge, been addressed
[17]. The aim of this study was to determine the associa-
tions of IGFBP-1, insulin, and C-peptide (a surrogate
biomarker of pancreatic insulin secretion), with colorec-
tal adenoma (adenomatous polyps) in the Diet and
Health study IV, in a majority White cohort and whether
these associations vary by gender.
Methods
Study population
Study participants in the Diet and Health Study IV were
drawn from outpatients who underwent screening col-
onoscopy between November 2001 and December 2002
at the University of North Carolina hospitals (Chapel
Hill, NC). Eligible subjects provided informed consent
and agreed to participate in a telephone interview, give
rectal biopsies or have blood drawn. Subjects were
excluded for the following reasons, incomplete examin-
ation (cecum not reached), age <30 years, inability to
give informed consent, polyposis (>100 polyps), previous
colon resection or cancer, colitis, and previous colon ad-
enoma. All histology and classification of colon polyps
in the study were performed as previously described
[17]. Advanced adenoma was defined as having an aden-
oma at least 1 cm in diameter, histology of villoglandularor villous or severe atypia. Individuals who had one or
more adenomatous polyps were defined as cases while
control subjects had no adenomatous polyps. The study
was approved by the School of Medicine institutional
review board at the University of North Carolina.
Data collection
The data collection was similar to previous protocols
[17,25,26]. Briefly, eligible and consenting participants
provided information about the time of last meal, (to
confirm an overnight fast) and the type of colonoscopy
preparation used. We also measured height, body
weight, and waist and hip circumference. A total of 1027
subjects were eligible, 123 (12%) refused to participate,
91 (9%) were not asked because the research assistant
was not available, and an additional 107 (10%) patients
were classified as ineligible after the colonoscopy due to
incomplete or unsatisfactory preparation. The study was
completed by 701 individuals, with a response rate of
76% (number interviewed/number eligible). Complete
information on insulin, C-peptide, IGFBP-1, adenomas
and apoptosis was available for 678 subjects. Enrolled
subjects completed telephone interviews about diet and
lifestyle within 12 weeks of colonoscopy. The lifestyle
questionnaire was used to collect data about demo-
graphics, family history, education, medical history,
physical activity, and other environmental factors. Diet-
ary information was collected using the NCI Diet His-
tory food frequency questionnaire that queried foods
and usual portion size (small, medium, or large) con-
sumed [27].
Biological specimens and laboratory assays
Specimens’ preparation and handling have been previously
described [8]. Subjects used either a balanced electrolyte
polyethylene glycol lavage or a phosphate-containing
purge prep prior to colonoscopy. At the beginning of the
endoscopic procedure, six mucosal pinch biopsies were
obtained 8 to 10 cm from the anal verge using standard
disposable, fenestrated colonoscopy forceps (Wilson-Cook,
Winston-Salem, NC). The same site was sampled in all
subjects. Blood samples were obtained prior to administra-
tion of medication through an i. v. catheter and processed
within 2–6 hours in the lab. Samples were kept at
4oC prior to processing. Plasma from the blood samples
was stored in aliquots at −80oC until assayed. Care was
taken to avoid repeated freezing and thawing of samples.
We analyzed samples from patients with excellent colonos-
copy preparation and confirmed overnight fast (based on
verbal response about last food intake and supportive evi-
dence of a clean colon). Circulating insulin, C-peptide
and IGFBP-1 levels were measured by ELISA using
reagents from Diagnostic Systems Laboratory (Webster,
TX). Laboratory personnel were blinded to the case or
Table 1 Descriptive characteristics of adenoma cases and
adenoma-free controls
Variable Cases
(N = 190)
Controls
(N = 488)
p-value
Mean Age in Years (SE) 56.8 (0.7) 55.7 (0.5) 0.19
White (%) 156 (82) 383 (78) 0.34
Male (%) 112 (59) 188 (39) 0.0001
Mean Body Mass Index (SE) 28.3 (0.4) 27.1 (0.3) 0.02
Family History of CRC (%) 28 (17) 60 (14) 0.37
Mean Dietary Fat (g/day) (SE) 70.8 (2.7) 68.6 (1.5) 0.47
Mean Alcohol1 (SE) 12.6 (1.7) 8.2 (0.7) 0.02
Mean Waist/hip Ratio (SE) 0.930 (0.008) 0.886 (0.007) 0.0001
Smokers (%) 29 (17) 49 (11) 0.06
Mean Monthly NSAID Use in
Past 5 Years (SE)
12.9 (2.0) 12.7 (1.4) 0.94
Mean Total Daily Calcium (mg) (SE) 744 (28) 785 (18) 0.23
Mean Red Meat (svgs/day) (SE) 1.73 (0.11) 1.47 (0.06) 0.03
Apoptosis (Morphology)2 3.33 (0.10) 3.76 (0.06) 0.0003
C-peptide (mean, se) 1.86 (0.10) 1.61 (0.08) 0.05
IGFBP-1 (mean, se) 21.3 (1.60) 24.1 (1.02) 0.13
Insulin (mean, se) 10.5 (0.8) 8.1 (0.5) 0.008
Number of Adenomas (mean, se) 1.58 (0.08) - -
Adenoma size (mean, se)3 6.21 (0.45) -
1 Daily grams from alcohol.
2Apoptosis – mean apoptotic cells per crypt.
3 Mean size of the largest adenoma.
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variation was 2.6% for insulin, 4.2% for C-peptide and 5.1%
for IGFBP-1. The inter-assay coefficient of variation was
<12% for insulin, C-peptide and IGFBP-1 measures.
Assays of apoptosis
Colonic biopsies were fixed in 10% buffered formalin
and processed by routine histology. Apoptosis was
scored by personnel who were trained by study patholo-
gist to differentiate between apoptosis and necrosis. A
subset of slides was re-scored by a second trained scorer
(TOK) in a blinded fashion. The inter-rater level of
agreement was >94%. We chose to use morphology to
assess apoptosis in this study based on our previous ex-
perience. Previously, we have used two methods, morph-
ology and TUNEL to assess apoptosis and found a high
level of correlation between the two methods (r = 0.73,
p = 0.01) [17].
Statistical analysis
Comparison of continuous and categorical variables be-
tween adenoma cases and non-adenoma controls were
made using t tests and Chi square tests, respectively.
The relationships between plasma insulin, C-peptide,
IGFBP-1 and colorectal adenomas were assessed in the
study population by comparing mean values between
case and control subjects using t tests. The distribution
of insulin, C-peptide, IGFBP-1 measures among control
subjects was used to generate quartile values. The lowest
quartile of each measure was considered as the refer-
ence. Apoptosis was expressed as the average number of
apoptotic cells per crypt. Using the median as cut point,
we divided apoptosis measures into lower half (below
the median) and upper half (above the median). Logistic
regression models were used to examine the association
between adenoma status and insulin, C-peptide, IGFBP-
1 or apoptosis. Confounder candidates for inclusion in
the model were age, race, sex, BMI, family history, total
fat intake, alcohol intake, waist to hip ratio, diabetes his-
tory, smoking status, NSAID use, calcium intake and red
meat intake. Each of these was added to a model con-
taining the main variable of interest (in quartiles) and if
at least two of the quartile parameter estimates changed
by more than 10% then the variable was considered a
potential confounder. All variables that met that stand-
ard were then entered into a backwards stepwise proced-
ure with the main variable of interest being forced into
the model.
In addition, we also performed the trend test to examine
for linear increase over quartile 1 to quartile 4 (p-trend).
The relationships between insulin, C-peptide, IGFBP-1
and BMI, and waist-to hip ratio (WHR) were assessed by
the Spearman correlation coefficient. In cases, we also
measured Spearman correlation coefficients betweennumber and size of adenomas and C-peptide, insulin and
IGFBP-1 levels.
Results
The characteristics of study participants are shown in
Table 1. Compared to controls (mean BMI = 27.1
se = 0.3), cases were significantly more likely to have
higher BMI (mean BMI = 28.3 se = 0.4), and increased
waist-hip ratio (WHR), mean WHR = 0.88 (se = 0.01) vs.
mean WHR = 0.93 (se = 0.01). A higher proportion of
cases reported increased consumption of alcohol and red
meat intake (mean = 1.7 svgs/day se = 0.11) than controls
(mean = 1.47 svgs/day se = 0.06). Apoptosis was also sig-
nificantly lower in cases than controls (p = 0.0003) while
the mean levels of circulating C-peptide (p = 0.05) and
insulin (p = 0.008) were significantly elevated in cases than
controls (Figure 1). Mean plasma IGFBP-1 was lower in
cases than controls but the results did not reach statistical
significance (Figure 1).
Table 2 summarizes the associations between plasma
insulin, C-peptide, IGFBP-1 and adenomas. Overall, ele-
vated C-peptide or insulin showed a positive association
with adenomas (p-trend ≤ 0.01). Compared to those with
the lowest quartile (Q1) of plasma insulin or C-peptide
Figure 1 Mean levels of circulating C-peptide, insulin and IGFBP-1 in adenoma cases and non-adenoma controls. C-peptide (p = 0.05)
and insulin (p = 0.008) levels were significantly elevated in cases compared to controls. Mean plasma IGFBP-1 was lower in cases than in controls
but the results did not reach statistical significance.
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were associated with a 2 to 5-fold increased risk of aden-
omas (OR = 3.5, 95% CI 1.7-7.4, p-trend = 0.002,
OR = 2.2, 95% CI 1.2-4.0, p-trend = 0.04, respectively). For
C-peptide these associations may be stronger in men (Q4
OR = 4.4, 95% CI 1.7-10.9, p-trend =0.006), than women
(OR = 1.6, 95% CI 0.7-4.0, p-trend = 0.58). Overall, asso-
ciations were stronger in the 3rd and 4th Q, for both C-
peptide and insulin (Table 2). On the other hand, we
found a statistically significant association between higher
levels of IGFBP-1 and reduced risk for adenoma in men
(OR = 0.3, 95% CI 0.1-0.7, p-trend = 0.0007). TheseTable 2 *Adjusted ORs and 95% CI for the relationship betwe
and among men and women
Overall
Measure Case/control (n) Adjusted OR1 (95% CI) Case/control (n)
C-Peptide
Quartile 1 29/106 1.0 (Referent) 14/40
Quartile 2 32/108 1.2 (0.6, 2.1) 19/42
Quartile 3 40/101 1.4 (0.8, 2.6) 24/40
Quartile 4 71/105 2.2 (1.2, 4.0) 48/45
P trend 0.04
IGFBP-1
Quartile 1 51/106 1.0 (Referent) 36/41
Quartile 2 52/103 0.9 (0.5, 1.6) 35/49
Quartile 3 37/105 0.7 (0.4, 1.2) 22/42
Quartile 4 29/105 0.6 (0.3, 1.1) 10/35
P trend 0.13
Insulin
Quartile 1 21/88 1.0 (Referent) 14/37
Quartile 2 27/84 1.7 (0.8, 3.7) 17/32
Quartile 3 40/81 2.6 (1.2, 5.5) 29/31
Quartile 4 55/84 3.5 (1.7, 7.4) 31/33
P trend 0.002
*Adjusted for race, sex, BMI, WHR, diabetes history, alcohol intake, smoking and redassociations remained unaltered after excluding BMI and
WHR from the statistical models.
We examined the relationship between apoptosis levels
and C-peptide, insulin and IGFBP1 in males and females.
We found no evidence for associations between levels of
C-peptide, insulin and IGFBP-1, and the apoptosis index,
among all individuals. However, restricting analyses for
overweight and obese individuals, we found that higher
C-peptide levels (>1st Q) were associated with increased
risk of lower apoptosis index (OR = 2.5, 95% CI 0.9-7.1, p-
trend = 0.048), an association that persisted in men
(OR = 6.3, 95% CI 1.0-36.7, p-trend = 0.04) (Table 3).en the C-peptide, IGFBP-1 and adenoma status, overall,
Men Women
Adjusted OR1 (95% CI) Case/control (n) Adjusted OR1 (95% CI)
1.0 (Referent) 15/66 1.0 (Referent)
1.9 (0.7, 4.8) 13/66 0.8 (0.3, 2.1)
2.6 (1.0, 6.9) 16/61 1.0 (0.4, 2.4)
4.4 (1.7, 10.9) 23/60 1.6 (0.7, 4.0)
0.006 0.58
1.0 (Referent) 15/65 1.0 (Referent)
0.7 (0.3, 1.5) 17/54 1.2 (0.5, 3.0)
0.5 (0.2, 1.0) 15/63 1.3 (0.5, 3.1)
0.3 (0.1, 0.7) 19/70 1.4 (0.6, 3.4)
0.007 0.47
1.0 (Referent) 7/51 1.0 (Referent)
1.3 (0.5, 3.5) 10/52 2.6 (0.7, 9.0)
3.1 (1.2, 7.9) 11/50 2.4 (0.7, 8.6)
2.8 (1.1, 7.1) 24/51 4.6 (1.5, 15.3)
0.02 0.03
meat intake.
Table 3 *Adjusted ORs and 95% CI for the relationship between the C-peptide, IGFBP-1 and low apoptosis, among
overweight and obese individuals (BMI > 30)
Overall Men Women
Measure Apoptosis (n, Lower/
upper half)
Adjusted
OR1 (95% CI)
Apoptosis (n, Lower/
upper half)
Adjusted
OR1 (95% CI)
Apoptosis (n, Lower/
upper half)
Adjusted
OR1 (95% CI)
C-Peptide
Quartile 1 12/16 1.0 (Referent) 6/7 1.0 (Referent) 6/9 1.0 (Referent)
Quartile 2 26/20 3.1 (1.0, 9.5) 9/11 4.4 (0.7, 30.0) 17/9 3.9 (0.9, 16.1)
Quartile 3 33/24 2.7 (0.9, 8.1) 17/9 7.0 (1.1,45.3) 16/15 1.9 (0.5, 7.3)
Quartile 4 54/45 2.5 (0.9, 7.1) 30/21 6.3 (1.1, 36.7) 24/24 1.5 (0.4, 5.5)
P trend 0.0465 0.04 0.30
IGFBP-1
Quartile 1 51/35 1.0 (Referent) 24/13 1.0 (Referent) 27/22 1.0 (Referent)
Quartile 2 44/33 0.9 (0.5, 1.9) 23/16 0.9 (0.3, 2.6) 21/17 1.0 (0.4, 2.5)
Quartile 3 22/19 0.9 (0.4, 2.1) 12/12 0.5 (0.1, 1.6) 10/7 1.4 (0.4, 4.9)
Quartile 4 8/18 0.3 (0.1, 1.0) 3/7 0.2 (0.03, 1.2) 5/11 0.4 (0.1, 1.5)
P trend 0.10 0.07 0.44
Insulin
Quartile 1 11/14 1.0 (Referent) 6/8 1.0 (Referent) 5/6 1.0 (Referent)
Quartile 2 25/17 1.6 (0.5, 5.1) 16/5 2.3 (0.4, 13.1) 9/12 1.1 (0.2, 5.5)
Quartile 3 33/25 1.3 (0.4, 3.9) 17/13 0.7 (0.1, 3.4) 16/12 1.7 (0.3, 8.5)
Quartile 4 40/32 1.5 (0.5, 4.4) 17/10 1.0 (0.2, 4.9) 23/22 1.6 (0.4, 7.1)
P trend 0.46 0.99 0.53
*Adjusted for race, sex, alcohol intake, diabetes history, smoking and red meat intake.
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individuals overall were associated with a reduced risk of
low apoptosis (OR = 0.3, 95% CI 0.1-1.0, p-trend = 0.10)
(Table 3). Further restricting analyses by sex revealed no
additional insights for IGFBP-1.
We also examined the relationship between insulin, C-
peptide, IGFBP-1, and obesity (BMI or waist-hip ratio
(WHR), which are factors related to colorectal adenomas,
CRC and insulin resistance (Table 4). In general, both insu-
lin and C-peptide showed strong negative correlations with
IGFBP-1. Both insulin and C-peptide showed highly signifi-
cant positive correlations with BMI and WHR. In addition,
there was strong inverse correlation between IGFBP-1 and
BMI (r = − 0.49, p = 0.0001), and IGFBP-1 and WHR
(r = −0.29, p = 0.0001) (Table 4). The associations for men
and women were comparable. Among adenoma cases, no
correlations were found for C-peptide, insulin or IGFBP-1
levels and either number of adenomas (r = 0.03, p = 0.65;
r = 0.004, p = 0.96; r = 0.06, p = 0.41, respectively) or aden-
oma size (r = −0.05, p = 0.50; r = 0.14, p = 0.06; r = −0.02,
p = 0.80, respectively).
Discussion and conclusion
In this study, we evaluated the relationship between in-
sulin, C-peptide and IGFBP-1 in relation to colorectal
adenomas and low apoptosis. We found that elevatedlevels of insulin and C-peptide predicted increased risk
of adenomas in men and women, while elevated levels of
IGFBP-1 reduced risk, particularly in men. The risk of
adenomas increased with increasing concentrations of
C-peptide and insulin, and decreased with increasing
concentrations of IGFBP-1. We also found that in over-
weight and obese individuals higher C-peptide increased
the risk of low apoptosis, particularly in men, whereas
elevated IGFBP-1 levels were associated with a reduced
risk of low apoptosis, an association that was stronger in
men. These findings suggest that the mechanism by
which these hormones increase risk of adenomas may
reflect their anti-apoptotic properties.
Insulin is secreted as pro-insulin and subsequently
cleaved into insulin and C-peptide. C-peptide is a marker
of pancreatic insulin synthesis, and several epidemiologic
studies have utilized C-peptide as an alternate biomarker
to insulin because it has a longer half-life than insulin and
therefore is more stable [28]. We found positive associa-
tions between insulin, C-peptide and adenomas, in both
men and women. While these findings contrast with those
by Yamaji et al., who found these associations only in men
in a Japanese cohort [24], they confirm both our previous
observations in an independent patient population [17],
and in a recent report in which we found race/ethnicity
differences for genes related to the IGF axis [29]. The
Table 4 Correlations between insulin, C-peptide, IGFBP-1 and BMI or WHR
C-Pep IGFBP-1 Insulin BMI Waist/Hip
C-Peptide 1 −0.38 (0.0001) 0.64 (0.0001) 0.45 (0.0001) 0.43 (0.0001)
IGFBP1 1 −0.36 (0.0001) −0.49 (0.0001) −0.29 (0.0001)
Insulin 1 0.45 (0.0001) 0.30 (0.0001)
BMI 1 0.35 (0.0001)
Waist/Hip 1
Men
C-Pep IGFBP-1 Insulin BMI Waist/Hip
C-Peptide 1 −0.28 (0.0001) 0.59 (0.0001) 0.43 (0.0001) 0.41 (0.0001)
IGFBP1 1 −0.36 (0.0001) −0.38 (0.0001) −0.10 (0.14)
Insulin 1 0.42 (0.0001) 0.28 (0.002)
BMI 1 0.36 (0.0001)
Waist/Hip 1
Women
C-Pep IGFBP-1 Insulin BMI Waist/Hip
C-Peptide 1 −0.43 (0.0001) 0.69 (0.0001) 0.46 (0.0001) 0.51 (0.0001)
IGFBP1 1 −0.36 (0.0001) −0.56 (0.0001) −0.39 (0.0001)
Insulin 1 0.48 (0.0001) 0.45 (0.0001)
BMI 1 0.43 (0.0001)
Waist/Hip 1
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and adenomas not only highlights the importance of the
insulin-IGF pathway in risk of colorectal adenomas and
cancer, but it also supports findings from previous studies
[19-21,29-31]. Higher IGFBP-1 levels were associated with
a reduced risk of adenomas. In these analyses, we did not
observe significant differences between cases and controls
for IGF-I; these findings are consistent with the hypothesis
that higher levels of insulin and C-peptide, and lower
levels of IGFBP-1 are the trigger points early in the disease
development. Overall, these findings are in agreement
with those of others [22], and support the hypothesis that
biologically available IGF-1 circulating levels may be an
etiologic factor in the formation of adenomas.
Only a limited number of studies have evaluated
IGFBP-1 in relation to adenomas or cancer [22,32,33]
but the results are inconsistent [19,21,24,29,34]. IGFBP-
1, a member of the IGF binding protein family binds to
IGF-I or IGF-II to regulate their bioavailability, in this
way acting as a modulator of cellular proliferation and
cell death [35]. IGFBP-1 can also inhibit metabolism of
IGFs [36], and IGFBP-1 expression is negatively regu-
lated by insulin [37]. Levels of circulating C-peptide and
insulin inversely correlate with plasma IGFBP-1 levels
[14], thus our findings support this observation. They
however contrast with a recent report [32] in which high
IGFBP-1 levels were inversely associated with colorectal
cancer in women, since we only observed statisticallysignificant associations in men. In a larger cohort, Le
Marchand et al. also observed a significantly reduced
adenoma risk with higher plasma IGFBP-1 levels [22].
Yamaji et al. reported similar associations in Japanese
men [24]. Our first attempt to test for IGFBP-1 associa-
tions with low apoptosis, showed that overweight and
obese individuals with higher C-peptide levels are more
likely to have low apoptosis.
Epidemiologic studies suggest that lifestyle and dietary
factors play an important role in the etiology of colorec-
tal cancer. In particular, obesity is associated with
increased risk of colon cancer, especially in men [38,39].
Men are also more likely to have higher waist-hip ratio,
a condition that is associated with elevated levels of
insulin and C-peptide [40,41]. Our findings show strong
positive correlations between insulin or C-peptide and
BMI or WHR among both men and women. In addition,
there was a strong inverse association between IGFBP-1
and BMI or WHR. These findings suggest that metabolic
characteristics associated with obesity and visceral adi-
posity may be important biomarkers of adenoma risk.
The major strengths of this study include availability
of fasting blood specimens, detailed information on
exposures and anthropometrics and ability to measure
apoptosis in normal mucosal biopsies and test for corre-
lations with circulating insulin, C-peptide or IGFBP-1
levels. There are some limitations of this study. Plasma
samples were only available for one-time measures of
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are similar to other studies that used one-time measures
of these analytes. Also, future studies should consider
measuring insulin resistance based on the Homeostatic
Model Assessment (HOMA).
In summary, we found significantly elevated levels of
insulin and C-peptide in patients with adenoma when
compared to adenoma-free controls. Elevated concentra-
tions of IGFBP-1 reduced the risk for adenomas in men.
These findings confirm our previous observations in an in-
dependent patient population and support the involvement
of the insulin-IGF pathway in the etiology of colorectal car-
cinogenesis. Elevated C-peptide and insulin significantly
predicted adenoma risk although C-peptide appeared a
stronger predictor of low apoptosis in overweight and
obese men than women. The strong positive association
between BMI and WHR, known colorectal cancer risk fac-
tors that are also related to hyperinsulinemia and the
insulin-IGF axis, suggests an interplay between obesity,
insulin-related factors and adenomas. Our findings suggest
that the anti-apoptotic properties of these peptide hor-
mones, particularly C-peptide, may be the primary driver
of associations with adenomas. Preventive measures to
reduce obesity and closer monitoring of individuals may be
beneficial to reducing adenoma and cancer risk.
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